SMALL LOT SIZES. GREAT SOLUTIONS.
Efficient small lot production on your pharma packaging machines
Both the pharmaceutical research industry and the generics industry are being confronted with challenges which are fundamentally changing methods of packaging medicines. Since the beginning of the decade and in the next few years also, a large number of the major pharma companies' blockbusters will lose patent protection. At the same time the development and licensing of new blockbusters is becoming more and more difficult.
In parallel, a structural change is taking place in the packaging of pharmaceutical products. The lot sizes of prescription medicines - original products as well as generics - are continuously falling. The trend towards small lot sizes has negative effects for the pharmaceutical industry. Up to 30% losses in terms of overall equipment effectiveness (OEE) are not a rarity.
Mediseal's answer: increases in OEE despite falling lot sizes
You may require skills relating to machines, line or processes: Mediseal has solutions for the many and varied challenges faced by the packaging industry. There are a number of variables you can act on to combat declining productivity due to shrinking lot sizes.
At the level of the individual machine or plant (line level). At site level. Or at corporate level.
At line level, the focus is on technical optimisation of the individual machine or system. High reliability, low maintenance, short set-up times and quick format changes ensure flexibility and cost-effectiveness.
At site level, Mediseal's LSC® "Late Stage Customisation" concept gives you the option of cleverly combining small batches of packaging and assembling them later. In our BIB BOB module, for example, standardised, unprinted or partly printed blisters are collected and later printed and cartoned together for specific customers - with the result that overall equipment effectiveness can be significantly increased.
We pursue an even more consistent bundling approach with our Mediseal "White Line" concept. Here the packaging of a pharmaceutical product takes place in a single production process, without the time-consuming and expensive conversion of the machine for specific national markets which would otherwise be necessary.
All elements for country-specific printing, such as the base film, continuous paper for inserts and white secondary packaging printed only with coloured logos, enter the packaging line blank, i.e. "white". During the packaging process these are printed inline with all country-specific data.
Your return on investment
Time-to-market: four to six weeks shorter
- Production start-up immediately after licensing in the respective country
- No lead times for the production of base film, inserts and folding boxes
Smaller amortisation and storage costs
- No destruction of stocks due to layout changes
- No capital tied up in inventory
- Customised production
Enhanced product protection
- Renewal of protection after expiry of patent protection by a maximum of 5 years (Supplementary Protection Certificate)
- Application for SPC at national level: many small lot sizes in the case of countries such as Malta, Cyprus or the Baltic states
Reduced costs per unit with small lot sizes
- Higher overall equipment effectiveness (OEE) thanks to significantly lower conversion costs
- Higher machine availability: country-specific layout can be changed in 10 minutes
Do you need more information?
We look forward to being of assistance!
Get in touch with us using the contact form. Or speak directly with our Solutions Manager.